Oliver Lagore Vanvalin Investment Group Buys Shares of 2,002 Stryker Corporation $SYK

Key Points

• Oliver Lagore Vanvalin Investment Group acquired 2,002 shares of Stryker Corporation, valued at approximately $745,000, during the second quarter.
• Analysts currently have a consensus rating of "Moderate Buy" for Stryker's stock, with an average price target of $430.33.
• Stryker recently declared a quarterly dividend of $0.84 per share, with a record date of September 30, contributing to an annualized yield of 0.9%.

Oliver Lagore Vanvalin Investment Group purchased a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,002 shares of the medical technology company's stock, valued at approximately $745,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Capital A Wealth Management LLC purchased a new position in Stryker during the fourth quarter valued at approximately $26,000. Goodman Advisory Group LLC purchased a new position in Stryker during the first quarter valued at approximately $32,000. City Holding Co. raised its position in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after acquiring an additional 74 shares in the last quarter. Ransom Advisory Ltd purchased a new position in Stryker during the first quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Stryker in the first quarter valued at approximately $40,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 1.4%

Shares of SYK stock traded down $5.27 during mid-day trading on Tuesday, hitting $372.95. 479,183 shares of the company's stock were exchanged, compared to its average volume of 1,390,097. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The stock has a market cap of $142.58 billion, a price-to-earnings ratio of 49.40, a PEG ratio of 2.71 and a beta of 0.93. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a 50-day simple moving average of $387.26 and a two-hundred day simple moving average of $379.05.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter last year, the firm earned $2.81 earnings per share. The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's payout ratio is presently 44.50%.

Insider Transactions at Stryker

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SYK. Truist Financial set a $415.00 price target on Stryker and gave the stock a "hold" rating in a research note on Monday, August 4th. Rothschild Redb upgraded Stryker to a "hold" rating in a report on Thursday, September 18th. BTIG Research reiterated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Needham & Company LLC upped their price target on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, Redburn Partners set a $420.00 price objective on Stryker in a report on Thursday, September 18th. Fourteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.